Pharmacogenetic Tests for Antipsychotic-Induced Weight Gain

E. O. Zhuravleva; N. Yu. Vel’ts; I. I. Snegireva; G. V. Kutekhova; R. N. Alyautdin

doi:10.1007/s11094-019-02059-z

Pharmacogenetic Tests for Antipsychotic-Induced Weight Gain

Авторлар: Zhuravleva E.O.¹, Vel’ts N.Y.¹, Snegireva I.I.¹, Kutekhova G.V.¹, Alyautdin R.N.¹
Мекемелер:
1. Ministry of Health of the Russian Federation, Scientific Center for Expert Evaluation of Medicinal Products
Шығарылым: Том 53, № 7 (2019)
Беттер: 668-671
Бөлім: Discussion
URL: https://journals.rcsi.science/0091-150X/article/view/245937
DOI: https://doi.org/10.1007/s11094-019-02059-z
ID: 245937

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат
Рұқсат жабық

Рұқсат берілді
Рұқсат жабық

Тек жазылушылар үшін

Аннотация
Авторлар туралы
Әдебиет тізімі
Қосымша файлдар
Статистика

Аннотация

Second-generation antipsychotic substances, as compared with first-generation antipsychotics, are more effective in relation to psychotic symptoms and have significantly lower potential for developing extrapyramidal impairments such as parkinsonism and late dyskinesia. However, use of these agents is associated with significant weight gain in patients. Advances in the pharmacogenetics of antipsychotic-induced weight gain are analyzed here.